Aclarion (NASDAQ:ACON – Get Free Report) and XWELL (NASDAQ:XWEL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
7.5% of Aclarion shares are held by institutional investors. Comparatively, 8.7% of XWELL shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 13.9% of XWELL shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Aclarion has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, XWELL has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclarion | $80,000.00 | 96.62 | -$7.23 million | ($17.01) | -0.20 |
| XWELL | $29.21 million | 0.32 | -$16.99 million | ($5.11) | -0.23 |
Aclarion has higher earnings, but lower revenue than XWELL. XWELL is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aclarion and XWELL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclarion | -9,517.11% | -52.31% | -49.79% |
| XWELL | -58.17% | -352.37% | -84.71% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Aclarion and XWELL, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclarion | 1 | 0 | 0 | 0 | 1.00 |
| XWELL | 1 | 0 | 0 | 0 | 1.00 |
Summary
Aclarion beats XWELL on 6 of the 11 factors compared between the two stocks.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
About XWELL
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
